Arbutus Biopharma (ABUS) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$1.4 billion.
- Arbutus Biopharma's Retained Earnings fell 316.91% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 316.91%. This contributed to the annual value of -$1.3 billion for FY2024, which is 547.68% down from last year.
- Latest data reveals that Arbutus Biopharma reported Retained Earnings of -$1.4 billion as of Q3 2025, which was down 316.91% from -$1.4 billion recorded in Q2 2025.
- Arbutus Biopharma's 5-year Retained Earnings high stood at -$1.1 billion for Q1 2021, and its period low was -$1.4 billion during Q3 2025.
- Over the past 5 years, Arbutus Biopharma's median Retained Earnings value was -$1.2 billion (recorded in 2023), while the average stood at -$1.2 billion.
- Per our database at Business Quant, Arbutus Biopharma's Retained Earnings plummeted by 845.02% in 2021 and then crashed by 316.91% in 2025.
- Over the past 5 years, Arbutus Biopharma's Retained Earnings (Quarter) stood at -$1.1 billion in 2021, then fell by 6.12% to -$1.2 billion in 2022, then fell by 6.05% to -$1.3 billion in 2023, then fell by 5.48% to -$1.3 billion in 2024, then fell by 2.21% to -$1.4 billion in 2025.
- Its Retained Earnings stands at -$1.4 billion for Q3 2025, versus -$1.4 billion for Q2 2025 and -$1.4 billion for Q1 2025.